Healthcare AI devices lacking publicly available clinical study information may be more likely to be recalled, according to a June 11 study published in JAMA Network Open. Researchers said the findings emphasize the importance of clinical validation and postmarket monitoring for AI-enabled medical devices.
Here are four notes from the study:
- Researchers examined 903 FDA-authorized AI-enabled medical devices approved between 1995 and 2024. Of those, 43 devices, or 4.8%, were recalled after a median of 458 days.
- Devices with missing information on supporting clinical studies were associated with a higher hazard of recall than devices backed by published clinical studies.
- Devices flagged in the CORE-MD postmarket surveillance tool and those identified in multiple surveillance databases showed higher recall risk than devices without reported safety signals.
- Incorrect use of an AI-enabled device was associated with a higher recall hazard. Researchers also found software-related problems and concerns involving device outputs were among the most frequently reported issues.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
